Latest news
Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea
Iconovo announces that the company will receive a grant of SEK 680,000 from Innowwide. The grant will be used to carry out a market study to introduce…
Biostock: Iconovo inleder 2024 med order från ledande läkemedelsbolag
Iconovo har erhållit en order från ett av världens tio största läkemedelsbolag. Dessutom stärker bolaget sin CDMO-affärsmodell genom att ingå ytterligare…
Press releases
Apr 24, 2025, 08:55
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Apr 24, 2025, 08:37
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
Apr 24, 2025, 08:37
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
Apr 24, 2025, 08:35
News
IR
English
Regulatory
MAR
Corporate Action
Other
Apr 24, 2025, 08:35
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Mar 31, 2025, 08:30
News
IR
English
Corporate Action
Other
Mar 31, 2025, 08:30
News
IR
Swedish
Corporate Action
Other
Mar 03, 2025, 13:42
News
IR
English
Corporate Action
Other
Mar 03, 2025, 13:42
News
IR
Swedish
Corporate Action
Other
Feb 27, 2025, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 27, 2025, 08:30
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
Jan 13, 2025, 08:30
News
IR
English
Corporate Action
Other
Jan 13, 2025, 08:30
News
IR
Swedish
Corporate Action
Other
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se